Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR)

A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors

To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).

Study Overview

• Status: Terminated
• Conditions: Renal Cell Carcinoma; Cervical Cancer; Solid Tumor; Mesothelioma; Melanoma (Skin); Oropharynx Cancer; HPV Positive Oropharyngeal Squamous Cell Carcinoma; Microsatellite Stable Colorectal Cancer; Cutaneous Squamous Cell Carcinoma
• Intervention / Treatment: Biological: TBio-6517; Biological: Pembrolizumab

Detailed Description

This is a Phase 1/2a dose escalation study with TBio-6517 administered by direct injection into tumor(s) or by intravenous infusion. The Phase 1 portion has 4 arms; the first arm (Arm A) will determine the RP2D of TBio-6517 alone when directly injected into tumor(s), and the second arm (Arm B) will determine the RP2D of TBio-6517 when combined with pembrolizumab. The third and fourth arms will determine the RP2D of TBio-6517 when given intravenously alone and with pembrolizumab, respectively.

In the Phase 2a portion, the clinical benefit of TBio-6517 combined with pembrolizumab will be further explored in patients with Microsatellite Stable Colorectal Cancer (MSS-CRC), Cholangiocarcinoma (CCA), Cutaneous Melanoma, and Cutaneous Squamous Cell Carcinoma of the Skin (cSCC), as assessed by overall response rate (ORR) from central radiology review.

• Study Type: Interventional
• Enrollment (Actual): 27
• Phase: Phase 1

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Ottawa, Ontario, Canada
      • Ottawa Hospital and Research Institute (OHRI)
• Korea, Republic of
  • Ilsandong, Korea, Republic of, 10408
    • National Cancer Center
  • Junggu, Korea, Republic of, 03080
    • Seoul National University Hospital (SNUH)
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85054
      • Mayo Clinic
  • Florida
    • Jacksonville, Florida, United States, 32224
      • Mayo Clinic
    • Miami, Florida, United States, 33136
      • Sylvester Comprehensive Cancer Center / UMHC
  • Kansas
    • Kansas City, Kansas, United States, 66205
      • University of Kansas Medical Center
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Clinical Site 1007
  • Minnesota
    • Rochester, Minnesota, United States, 55902
      • Mayo Clinic
  • Montana
    • Billings, Montana, United States, 31031
      • The Billings Clinic
  • Texas
    • Houston, Texas, United States, 77030
      • University of Texas MD Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Key Inclusion Criteria:

• Have a histologically or pathologically documented, locally-advanced or metastatic solid tumor for which standard curative measures do not exist or are no longer effective
• Measurable disease as per RECIST 1.1 criteria
• At least one tumor amenable to safe ITu injections and biopsies
• ECOG performance status 0 or 1
• Demonstrate adequate organ function
• Must be willing to comply with all protocol procedures and adhere to post-treatment care instructions
• Additional Inclusion criteria exist

For patients in phase 2 only: Have a histologically or cytologically confirmed advanced (metastatic and/or unresectable) solid tumor listed below, that is incurable and for which prior standard treatment has failed:

1. Advanced (unresectable) or metastatic, intra or extra hepatic adenocarcinoma originating from the bile duct, CCA (Cohort 1) having progressed on at least 1 line of systemic therapy (including targeted therapy if eligible)
2. Locally advanced or metastatic cutaneous melanoma (Cohort 2) that has failed anti-PD-1 or anti-PDL1 therapy (+/- anti-CTLA-4 therapy) and if BRAF+, having failed a BRAF/ +/-MEK inhibitor
3. Locally advanced or metastatic cSCC (Cohort 3) that has not received systemic therapy (e.g., local resection or local topical therapy is permitted).
4. Locally advanced or metastatic MSS-CRC (Cohort 4) patients that have progressed on at least 2 prior lines of systemic therapy which should include irinotecan and oxaliplatin +/- targeted therapy if warranted.

Key Exclusion Criteria:

• Prior systemic therapy, including experimental, surgery or radiation therapy within 4 weeks and must have recovered from acute toxicity.
• Prior treatment with any oncolytic virus.
• Requires use of anti-platelet or anti-coagulant therapy that cannot be safely suspended for per protocol biopsies or intra-tumoral injections.
• CNS metastases and/or carcinomatous meningitis that have not been completely resected or completely irradiated.
• Prior history of myocarditis
• Symptomatic or asymptomatic cardiovascular disease
• Known HIV/AIDS, active HBV or HCV infection.
• Received immunosuppressive medication within 4 weeks. (>10mg/day prednisone)
• Known intolerance to anti-PD-1 or anti-PD-L1 antibody therapy
• Additional Exclusion criteria exist

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A: TBio-6517 alone; Dose escalation of TBio-6517 alone administered by direct injection into tumor(s) x 4. Booster injections of TBio-6517 are permitted for up to 24 months.	Biological: TBio-6517; Engineered Oncolytic Vaccinia Virus; Other Names: RIVAL-01
Experimental: Arm B: TBio-6517 and Pembrolizumab; Dose escalation of TBio-6517 administered in combination with pembrolizumab. TBio-6517 will be directly injected into tumor(s) x 4. Booster injections of TBio-6517 are permitted for up to 24 months. Pembrolizumab will be administered beginning at Day 9 via intravenous (IV) infusion every 3 weeks for up to 24 months.	Biological: TBio-6517; Engineered Oncolytic Vaccinia Virus; Other Names: RIVAL-01; Biological: Pembrolizumab; Immune checkpoint inhibitor.; Other Names: Keytruda
Experimental: TBio-6517 and Pembrolizumab in MSS-CRC; Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 9 given every 3 weeks for up to 24 months in patients with microsatellite stable colorectal carcinoma (MSS-CRC). Booster injections of TBio-6517 are permitted for up to 24 months.	Biological: TBio-6517; Engineered Oncolytic Vaccinia Virus; Other Names: RIVAL-01; Biological: Pembrolizumab; Immune checkpoint inhibitor.; Other Names: Keytruda
Experimental: TBio-6517 and Pembrolizumab in cutaneous melanoma; Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 9 given every 3 weeks for up to 24 months in patients with malignant melanoma of the skin. Booster injections of TBio-6517 are permitted for up to 24 months.	Biological: TBio-6517; Engineered Oncolytic Vaccinia Virus; Other Names: RIVAL-01; Biological: Pembrolizumab; Immune checkpoint inhibitor.; Other Names: Keytruda
Experimental: TBio-6517 and Pembrolizumab in cutaneous squamous cell carcinoma of the skin; Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 8 given every 3 weeks for up to 24 months in patients with cSCC. Booster injections of TBio-6517 are permitted for up to 24 months.	Biological: TBio-6517; Engineered Oncolytic Vaccinia Virus; Other Names: RIVAL-01; Biological: Pembrolizumab; Immune checkpoint inhibitor.; Other Names: Keytruda
Experimental: TBio-6517 and Pembrolizumab in HPV positive head and neck cancer; Doses of TBio-6517 will be administered by direct injection into tumor(s) x 4 in combination with pembrolizumab beginning at Day 9 given every 3 weeks for up to 24 months in patients with HPV associated oropharyngeal cancer. Booster injections of TBio-6517 are permitted for up to 24 months.	Biological: TBio-6517; Engineered Oncolytic Vaccinia Virus; Other Names: RIVAL-01; Biological: Pembrolizumab; Immune checkpoint inhibitor.; Other Names: Keytruda
Experimental: Arm C: TBio-6517 intravenous; Dose escalation of TBio-6517 alone administered by intravenous infusion x 4. Booster infusions of TBio-6517 are permitted for up to 24 months.	Biological: TBio-6517; Engineered Oncolytic Vaccinia Virus; Other Names: RIVAL-01
Experimental: Arm D: TBio-6517 intravenous and Pembrolizumab; Dose escalation of TBio-6517 administered in combination with pembrolizumab. Dose escalation of TBio-6517 alone administered by intravenous infusion x 4. Booster infusions of TBio-6517 are permitted for up to 24 months. Pembrolizumab will be administered beginning at Day 9 via intravenous (IV) infusion every 3 weeks for up to 24 months.	Biological: TBio-6517; Engineered Oncolytic Vaccinia Virus; Other Names: RIVAL-01; Biological: Pembrolizumab; Immune checkpoint inhibitor.; Other Names: Keytruda

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of adverse events when TBio-6517 administered by direct injection into tumor(s) alone at each dose level	Percentage of patients with adverse events by grade as determined by NCI CTCAE v5.0	25 months
Incidence of adverse events when TBio-6517 administered by direct injection into tumor(s) when combined with pembrolizumab	Percentage of patients with adverse events by severity as determined by NCI CTCAE v5.0	25 months
Maximum tolerated dose (MTD) or Maximum feasible dose (MFD) and determination of the recommended Phase 2 dose (RP2D) of TBio-6517 alone and in combination with pembrolizumab.	The highest dose of TBio-6517 that can be administered where fewer than 2 patients have a dose-limiting safety event alone or when combined with pembrolizumab as assessed by NCI CTCAE v.5.0 during the Phase 1 dose escalation	4 weeks
Percentage of overall response rate (ORR) by RECIST 1.1 at the RP2D	Percentage of patients treated at the RP2D in combination with pembrolizumab with a partial response or complete response by RECIST 1.1 following central radiologist review	25 months
Percentage of overall response rate (ORR) by immunotherapy RECIST (iRECIST) at the RP2D	Percentage of patients treated at the RP2D with pembrolizumab with a partial response (PR) or complete response (CR) by iRECIST following central radiologist review	25 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number and severity of adverse events at the RP2D	Number of patients with adverse events by severity and frequency as determined by NCI CTCAE v5.0	25 months
Median overall survival (OS)	Median overall survival in months in patients	48 months
Median Duration of Response (DoR)	Median duration of response in patients with a CR or PR	25 months
Proportion of patients with a response (ORR)	Percentage of patients in all arms with a CR or PR as assessed by the central radiologist using RECIST 1.1 and iRECIST	25 months
Median Disease Control Rate (DCR)	Median duration of response in patients with a CR, PR, or stable disease (SD)	25 months
Time to tumor progression (TTP)	Median time until patient disease progression (PD)	25 months
Median progression free survival	Median duration of progression free survival of patients	25 months

Collaborators and Investigators

• Sponsor: Turnstone Biologics, Corp.
• Collaborators: Takeda
• Investigators: Study Director: Ines Verdon, MD, Turnstone Biologics

Study record dates

Study Major Dates

• Study Start (Actual): June 2, 2020
• Primary Completion (Actual): January 23, 2023
• Study Completion (Actual): January 23, 2023

Study Registration Dates

• First Submitted: March 4, 2020
• First Submitted That Met QC Criteria: March 6, 2020
• First Posted (Actual): March 9, 2020

Study Record Updates

• Last Update Posted (Actual): April 23, 2025
• Last Update Submitted That Met QC Criteria: April 17, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Keywords: mesothelioma; melanoma; CRC; cervical cancer; skin cancer; Oncolytic Virus; Intratumoral injection; MSS-CRC; oropharyngeal; Renal Cell; HPV cancer
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Stomatognathic Diseases; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Respiratory Tract Diseases; Neoplasms by Histologic Type; Uterine Diseases; Genital Diseases, Female; Lung Diseases; Head and Neck Neoplasms; Neoplasms, Glandular and Epithelial; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Genital Neoplasms, Female; Adenoma; Neoplasms, Mesothelial; Pleural Neoplasms; Skin Diseases; Neoplasms, Squamous Cell; Uterine Cervical Diseases; Otorhinolaryngologic Diseases; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Uterine Neoplasms; Neuroendocrine Tumors; Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Pharyngeal Diseases; Nevi and Melanomas; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck; Mesothelioma, Malignant; Carcinoma; Mesothelioma; Carcinoma, Squamous Cell; Uterine Cervical Neoplasms; Melanoma; Oropharyngeal Neoplasms; Antineoplastic Agents, Immunological; Immune Checkpoint Inhibitors; Antineoplastic Agents; Molecular Mechanisms of Pharmacological Action; Pembrolizumab
• Other Study ID Numbers: TBio-6517-ITu-001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No